Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

The adequacy of phosphorus binder prescriptions among American hemodialysis patients.

Huml AM, Sullivan CM, Leon JB, Sehgal AR.

Ren Fail. 2012;34(10):1258-63. doi: 10.3109/0886022X.2012.718724.

2.

Benefits of sevelamer on markers of bone turnover in Taiwanese hemodialysis patients.

Lin YF, Chen YM, Hung KY, Chu TS, Kan WC, Huang CY, Lin SL, Kao TW, Huang JW, Chiang WC, Yen CJ, Tsai TJ, Wu KD, Wu MS.

J Formos Med Assoc. 2010 Sep;109(9):663-72. doi: 10.1016/S0929-6646(10)60107-6.

3.

A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients.

Liu YL, Lin HH, Yu CC, Kuo HL, Yang YF, Chou CY, Lin PW, Liu JH, Liao PY, Huang CC.

Ren Fail. 2006;28(8):701-7.

PMID:
17162430
4.

Reasons for phosphate binder discontinuation vary by binder type.

Wang S, Anum EA, Ramakrishnan K, Alfieri T, Braunhofer P, Newsome B.

J Ren Nutr. 2014 Mar;24(2):105-9. doi: 10.1053/j.jrn.2013.11.004.

PMID:
24462496
5.

Phosphate binder impact on bone remodeling and coronary calcification--results from the BRiC study.

Barreto DV, Barreto Fde C, de Carvalho AB, Cuppari L, Draibe SA, Dalboni MA, Moyses RM, Neves KR, Jorgetti V, Miname M, Santos RD, Canziani ME.

Nephron Clin Pract. 2008;110(4):c273-83. doi: 10.1159/000170783.

PMID:
19001830
6.

Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.

Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF.

Am J Kidney Dis. 2009 Oct;54(4):619-37. doi: 10.1053/j.ajkd.2009.06.004. Review.

PMID:
19692157
8.

Sevelamer reduces calcium load and maintains a low calcium-phosphorus ion product in dialysis patients.

Gallieni M, Cozzolino M, Carpani P, Zoni U, Brancaccio D.

J Nephrol. 2001 May-Jun;14(3):176-83.

PMID:
11439741
9.

The economic impact of improving phosphate binder therapy adherence and attainment of guideline phosphorus goals in hemodialysis patients: a Medicare cost-offset model.

Ramakrishnan K, Braunhofer P, Newsome B, Lubeck D, Wang S, Deuson J, Claxton AJ.

Adv Ther. 2014 Dec;31(12):1272-86. doi: 10.1007/s12325-014-0170-4.

PMID:
25479935
10.

A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.

Prajapati VA, Galani VJ, Shah PR.

Saudi J Kidney Dis Transpl. 2014 May;25(3):530-8.

11.

Sevelamer hydrochloride in peritoneal dialysis patients: results of a multicenter cross-sectional study.

Ramos R, Moreso F, Borras M, Ponz E, Buades JM, Teixidó J, Morey A, Garcia C, Vera M, Doñate MT, de Arellano MR, Barbosa F, González MT.

Perit Dial Int. 2007 Nov-Dec;27(6):697-701.

13.

Management of hyperphosphataemia in dialysis patients: role of phosphate binders in the elderly.

Lorenzo Sellares V, Torres Ramírez A.

Drugs Aging. 2004;21(3):153-65. Review.

PMID:
14979734
14.

[Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].

Lorenzo Sellares V, Torregrosa V.

Nefrologia. 2008;28 Suppl 3:67-78. Spanish.

15.
16.

Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.

Chen N, Wu X, Ding X, Mei C, Fu P, Jiang G, Li X, Chen J, Liu B, La Y, Hou F, Ni Z, Fu J, Xing C, Yu X, Huang C, Zuo L, Wang L, Hunter J, Dillon M, Plone M, Neylan J.

Nephrol Dial Transplant. 2014 Jan;29(1):152-60. doi: 10.1093/ndt/gft232.

17.

Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients.

Nolan CR, Qunibi WY.

Curr Opin Nephrol Hypertens. 2003 Jul;12(4):373-9. Review.

PMID:
12815333
18.

[Phosphorus binders: preferences of patients on haemodialysis and its impact on treatment compliance and phosphorus control].

Arenas MD, Malek T, Álvarez-Ude F, Gil MT, Moledous A, Reig-Ferrer A.

Nefrologia. 2010;30(5):522-30. doi: 10.3265/Nefrologia.pre2010.may.10275. Spanish.

19.

Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study.

Sprague SM, Ross EA, Nath SD, Zhang P, Pratt RD, Krause R.

Clin Nephrol. 2009 Oct;72(4):252-8.

PMID:
19825330
20.

Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability.

de Francisco AL, Leidig M, Covic AC, Ketteler M, Benedyk-Lorens E, Mircescu GM, Scholz C, Ponce P, Passlick-Deetjen J.

Nephrol Dial Transplant. 2010 Nov;25(11):3707-17. doi: 10.1093/ndt/gfq292.

Items per page

Supplemental Content

Support Center